I'd like to see some Market Preparation first , signalling to market that the "Significant Phase II last Interim Data is going to be presented this month" prior to a May June full Phase II Data Set being announced..
Messaging seems reactive here at SNT not proactive ... for instance look at the SNT 6302 data drop ,,, SP races to 9.5c then no editorial to push the news to the wider market ,,, it's not what management knows but what the Market are aware of that encourages Investment toward a Company..
Whats hugely important is that SNT 5505 has already been Awarded Orphan Drug Designation by the FDA... once the final Data in May/June is delivered then Syntara are smack in the sweet spot for a deal,,, now I'd rather see a deal with a strong SP as our base...
We saw a few weeks ago the addressable market for the SNT 6302 ,,, IMHO if Fiona directly applied for TGA approval next week you would be seeing SNT 6302 scripted for Public Use by Christmas ,,, Dermal Application of Topical Creams is low hanging fruit ,,, NZT
SNT Price at posting:
7.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)